Showing 1751-1760 of 2123 results for "".
- Cenobamate Continuation for Over 6 Years Represents Long-Term Efficacy and Safetyhttps://practicalneurology.com/news/cenobamate-continuation-for-over-6-years-represents-long-term-efficacy-and-safety/2469643/In the long-term open-label extension of a randomized double-blind placebo-controlled study of adjunctive treatment for epilepsy with cenobamate (Xcopri; SK LIfe Science, Paramus, NJ)treatment duration averaged 6.25 years (200 mg median modal daily dose, range 50 to 400 mg). Initial enr
- Risdiplam Improvements in Motor Function Continue Over 1 Year of Treatment in Infancy to Adulthoodhttps://practicalneurology.com/news/risdiplam-improvements-in-motor-function-continue-over-1-year-of-treatment-in-infancy-to-adulthood/2469613/In the JEWELFISH study (NCT03032172), individuals age 1 to 60 years with spinal muscular atrophy (SMA) who were treated with risdiplam (Evrysdi; Genentech, South San Francisco, CA) had more than a twofold increase in SMN protein levels
- Deep Brain Stimulation Remains Effective for Parkinson Disease After 15 Yearshttps://practicalneurology.com/news/deep-brain-stimulation-remains-effective-for-parkinson-disease-after-15-years/2469605/According to a study published in Neurology, deep brain stimulation (DBS) continues to be effective for treating symptoms of Parkinson disease (PD) 15 years after implantation. Over a 15-year period, people with PD treated with DBS had a 75% reduction from baseline in dyskinesia, 59% less "O
- Commercial Coverage of MR-guided Focused Ultrasound for Essential Tremorhttps://practicalneurology.com/news/commercial-coverage-of-mr-guided-focused-ultrasound-for-essential-tremor/2469585/Aetna (Hartford, CT) has announced they will provide insurance coverage for MR-guided Focused Ultrasound (FUS) for treating medication-refractory essential tremor (ET). This treatment is availabe at over 60 treatment centers and employs ultrasound waves to create targeted zones of therapeutic the
- Lamotrigine, Levetiracetam and Other Antiseizure Medications During Pregnancy Not Associated With Developmental Delays at Age 3 Yearshttps://practicalneurology.com/news/lamotrigine-levetiracetam-and-other-antiseizure-medications-during-pregnancy-not-associated-with-developmental-delays-at-age-3-years/2469520/According to a preliminary study, children born to women taking certain antiseizure medications (ASMs) for epilepsy during pregnancy had no higher risk of developmental delays at age 3 years when compared with children of women without epilepsy. The study involved 275 individuals
- Kidney Problems as a Young Adult May Affect Cognitive Function in Midlifehttps://practicalneurology.com/news/kidney-problems-as-a-young-adult-may-affect-cognitive-function-in-midlife/2469370/Individuals may experience worse cognitive function during midlife if they had moderate-to-high risk of kidney failure as a young adult, according to a study published in Neurology. “We know that people wit
- Children With Duchenne Muscular Dystrophy Receiving Ataluren Treatment Were Able to Walk Independently for an Additional 3.5 Yearshttps://practicalneurology.com/news/children-with-duchenne-muscular-dystrophy-receiving-ataluren-treatment-were-able-to-walk-independently-for-an-additional-35-years/2469147/Real-world data showing that boys with Duchenne muscular dystrophy (DMD) treated with ataluren (Translarn, PTC Therapeutics, Inc., South Plainfield, NJ) preserved the ability to walk for 3.5 years longer than given standard-of-care (SoC) treatment alone. Pulmonary function was also preserved in t
- Young Black and Latino People May Fare Better Than Whites After Hemorrhagic Strokehttps://practicalneurology.com/news/young-black-and-latino-people-may-fare-better-than-whites-after-hemorrhagic-stroke/2469136/Young black and Latino people may be less likely than young white people to be disabled or even die within 3 months of a hemorrhagic stroke. This is reported in a clinical study published in Neurology, which focused on younger people who have had hemorrhagic stroke. Of whites in the stu
- Concussion Effects May Linger More Than a Year After Return to Playhttps://practicalneurology.com/news/concussion-effects-may-linger-more-than-a-year-after-return-to-play/2469051/New research published in Neurology has found athletes’ brains may still not be fully recovered 1 year after being allowed to return to play. The study involved 24 college athletes with concuss
- Gene Therapy for Children Age 6 Months to 5 Years with Spinal Muscular Atrophy Type 2 Effective in Clinical Trialhttps://practicalneurology.com/news/gene-therapy-for-children-age-6-months-to-5-years-with-spinal-muscular-atrophy-type-2-effective-in-clinical-trial/2469042/Children age 6 months to 5 years with spinal muscular atrophy (SMA), treated with onasemnogene (AVXS-101; Zolgensma, Bannockburn, IL) are showing improvements in motor function. In the STRONG (NCT03381729) phase 1/2 clinical study, 1 of